Clinical trials: Pembrolizumab
Solid Tumor, Lymphoma
Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma.
- Trial name
- NCT03934814
- Testing
- TJ011133, Pembrolizumab, Rituximab
- Where
- 21 sites in United States, China
- Volunteers
- 98 people
- Sponsor
- I-Mab Biopharma US Limited
Hodgkin Lymphoma
PD-1 Inhibitors Maintenance for cHL Post-autoHCT
This phase II study is designed to determine the clinical efficacy of PD-1 inhibitors, administered as maintenance therapy after autologous stem cell transplant (autoHCT), in patients with relapsed or refractory (R/R) classical…
- Trial name
- NCT06812858
- Testing
- Nivolumab, Pembrolizumab
- Where
- 4 sites in Kazakhstan, Russia
- Volunteers
- 83 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Carcinoma, Non-Small-Cell Lung, Urothelial Carcinoma
A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors
This study will consider the safety and effectiveness of a study drug, CAN04, in combination with pembrolizumab, in the treatment of incurable or metastatic non-small-cell lung cancer (NSCLC), head and neck squamous cell…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Urothelial Carcinoma, Malignant Melanoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT04452214
- Testing
- CAN04, Pembrolizumab, Carboplatin
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Cantargia AB
Renal Cell Carcinoma, Brain Metastasis
Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases
This is a multi-center, open-label phase II study evaluating the efficacy and safety of pembrolizumab in combination with lenvatinib in patients with renal cell carcinoma (RCC) and brain metastasis who were previously treated…
- Trial name
- NCT07011849
- Testing
- Pembrolizumab, Lenvatinib
- Sponsor
- M.D. Anderson Cancer Center
Non-small Cell Lung Cancer, NSCLC
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; MK-2870) in first-line…
- Trial name
- NCT06422143
- Testing
- Pembrolizumab, sac-TMT, Carboplatin
- Where
- 217 sites in United States, Argentina and 24 more
- Volunteers
- 851 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Solid Tumors, Triple Negative Breast Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
The purpose of this study is to determine the safety and efficacy of combination therapy with pembrolizumab (MK-3475) and lenvatinib (E7080/MK-7902) in participants with triple negative breast cancer (TNBC), ovarian cancer…
- Conditions
- Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer, Gastric Cancer
- Trial name
- NCT03797326
- Testing
- Pembrolizumab, Lenvatinib
- Where
- 88 sites in United States, Argentina and 15 more
- Volunteers
- 611 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous…
- Trial name
- NCT06692738
- Testing
- Rilvegostomig, Pembrolizumab, Carboplatin
- Where
- 333 sites in United States, Argentina and 24 more
- Volunteers
- 1,160 people
- Sponsor
- AstraZeneca
SCC - Squamous Cell Carcinoma of Skin
Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.
This is an open-label, "non comparative", non-randomized, Phase II study. Patients will be enrolled in 2 treatment arms
- Trial name
- NCT04812535
- Testing
- Vilobelimab, Vilobelimab + pembrolizumab combination therapy
- Where
- 25 sites in United States, Belgium and 3 more
- Volunteers
- 30 people
- Sponsor
- InflaRx GmbH
Recurrent Respiratory Papillomatosis
Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients
This research study is evaluating an immune modulatory agent as a possible treatment for patients with Recurrent Respiratory Papillomatosis (RRP) with significant disease involving the larynx, trachea, and/or lungs.
- Trial name
- NCT02632344
- Testing
- Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Massachusetts General Hospital
Non-squamous Non-small Cell Lung Cancer
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with locally…
- Trial name
- NCT06627647
- Testing
- Rilvegostomig, Pembrolizumab, Carboplatin
- Where
- 301 sites in United States, Argentina and 23 more
- Volunteers
- 1,160 people
- Sponsor
- AstraZeneca
Metastatic Triple Negative Breast Cancer
Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer
The purpose of this study is to see how effective the combination of the two chemotherapy drugs (carboplatin and nab-paclitaxel) are when added to a third drug, pembrolizumab.
- Trial name
- NCT03121352
- Testing
- Carboplatin, Nab-paclitaxel, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Case Comprehensive Cancer Center
Solid Tumor, Lymphoma
Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001)
The purposes of this study are to: 1) assess the safety and tolerability and 2) establish a preliminary recommended Phase 2 dose (RP2D) and/or a maximum tolerated dose (MTD) or a maximum administered dose (MAD) of MK-2118 when…
- Trial name
- NCT03249792
- Testing
- MK-2118 (IT), MK-2118 (SC), Pembrolizumab
- Where
- 8 sites in United States, Israel
- Volunteers
- 140 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Microsatellite Stable Colorectal Carcinoma, Recurrent Colorectal Carcinoma
Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)
The phase II trial tests whether pembrolizumab and dendritic cell-based treatment works to shrink tumors in patients with colorectal cancer that does not respond to treatment (refractory).
- Conditions
- Metastatic Microsatellite Stable Colorectal Carcinoma, Recurrent Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8
- Trial name
- NCT05518032
- Testing
- Biopsy, Pembrolizumab, Therapeutic Autologous Dendritic Cells
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Esophageal Carcinoma, Esophagogastric Junction Carcinoma
Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)
In this study, participants with advanced or metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or Siewert type I adenocarcinoma of the esophagogastric junction (EGJ) that had progressed after first-line…
- Trial name
- NCT02564263
- Testing
- pembrolizumab, paclitaxel, docetaxel
- Volunteers
- 628 people
- Sponsor
- Merck Sharp & Dohme LLC
High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma
Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients
This pilot clinical trial studies the effect of pembrolizumab and lenvatinib in treating patients with high-grade serous ovarian cancers.
- Conditions
- High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Peritoneal High Grade Serous Adenocarcinoma, Recurrent High Grade Fallopian Tube Serous Adenocarcinoma
- Trial name
- NCT05114421
- Testing
- Lenvatinib, Pembrolizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumor
A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors
A Multicenter, Open-Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors
- Trial name
- NCT05176509
- Testing
- YH003, YH001, Pembrolizumab
- Where
- 4 sites in Australia
- Volunteers
- 5 people
- Sponsor
- Eucure (Beijing) Biopharma Co., Ltd
Skin Melanoma, Squamous Non-small-cell Lung Cancer
Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms
The goal of this double-blind, randomized study is to establish the equivalence of pharmacokinetic properties, as well as the comparability of safety, immunogenicity and pharmacodynamics of the drug RPH-075 (international…
- Conditions
- Skin Melanoma, Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT06307093
- Testing
- RPH-075, Keytruda®
- Where
- 23 sites in Russia
- Volunteers
- 90 people
- Sponsor
- R-Pharm
Advanced Solid Tumor Malignancy
Study of KBA1412 in Participants With Advanced Solid Malignant Tumors
The purpose of this trial is to assess the safety and efficacy of KBA1412, a patient derived, fully human, monoclonal antibody targeting CD9, in patients with advanced solid malignant tumors
- Trial name
- NCT05501821
- Testing
- KBA1412, Pembrolizumab
- Where
- 5 sites in Belgium, Netherlands
- Volunteers
- 16 people
- Sponsor
- Kling Biotherapeutics B.V.
Metastatic Colorectal Cancer
Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC).
Colorectal Cancer (CRC) is a leading cause of cancer-related death. Around 30% of patients present with advanced disease and 50% of those that attempt curative surgery will eventually relapse.
- Trial name
- PEMBROLA (NCT05201612)
- Testing
- Olaparib, Pembrolizumab
- Where
- 15 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
HNSCC
A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SirH&N Trial)
This is a non-randomized, open-label, dose-escalation and dose-expansion phase I/II clinical study to evaluate the safety, tolerability, and efficacy of HCB101 in combination with pembrolizumab in patients with…
- Trial name
- NCT07136545
- Testing
- HCB101, Pembrolizumab
- Where
- 3 sites in Taiwan
- Volunteers
- 50 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.